Minireviews
Copyright ©The Author(s) 2024.
World J Transplant. Mar 18, 2024; 14(1): 89978
Published online Mar 18, 2024. doi: 10.5500/wjt.v14.i1.89978
Table 1 Pre-transplant screening and diagnostic work-up for kidney transplant recipients
CMVCMV IgG serology in both donors and recipients
EBVScreening by EBV serology in both donors and recipients
BKPyVNot done at present
HSVHSV antibodies in blood
VZVPretransplant screening for previous VZV infectio
Hepatitis B & CHBV
HBsAg and antibody to hepatitis B core antigen (antiHBc)
HCV
HCV antibody test
Respiratory virusesNasopharyngeal wash or bronchoalveolar lavage fluid (BAL) specimens (in the case of Adeno virus - stools or plasma), by conventional viral culture, PCR, or direct immunofluorescence
Table 2 Post-transplant screening and diagnostic work-up for kidney transplant recipients
CMVQuantitative CMV viral load
Diagnosis- presence of CMV DNA in whole blood or plasma
Tissue biopsy
Diagnosis- presence of CMV inclusion or immunostaining
CMV serology
Diagnosis- presence of CMV IgG post kidney transplantation in
CMV R- patients
EBVQuantitative EBV viral load
Tissue biopsy
EBV serology
BKPyVUrine cytology
Quantitative BK viral load in urine
Quantitative BK viral load in plasma
Allograft biopsy
HSVDirect fluorescence antibody for HSV from vesicular lesions or PCR from CSF or visceral tissue samples
VZVDirect fluorescence antibody for VZV from vesicular lesions or PCR from CSF or visceral tissue samples
Hepatitis B & CHBV
HBsAg and antibody to hepatitis B core antigen (antiHBc)
HCV
HCV antibody test
Respiratory virusesNasopharyngeal wash or bronchoalveolar lavage fluid (BAL) specimens, (in the case of Adeno virus - stools or plasma), by conventional viral culture, PCR, or direct immunofluorescence
Table 3 Treatment of viral infections kidney transplant recipients
CMVCMV load copy no < 500 - below quantifiable level - no action
CMV load copy no 500-3000 - active CMV infection - repeat CMV in 1 week, consider treatment if clinically indicated
CMV load copy no > 3000 - Active CMV infection - commence pre-emptive treatment
Intravenous ganciclovir or oral valganciclovir
EBVImmunosuppressive drug reduction
Ganciclovir and valganciclovir have antiviral impact against EBV
BKPyVImmunosuppressive drug reduction
No specific antiviral therapy
HSVAcyclovir
Intravenous or oral
VZVIntravenous acyclovir, while less severe infection can be treated with oral acyclovir
Hepatitis B & CImmunosuppressive drug reduction
Hepatitis B – Lamivudine
Hepatitis C - IFN and ribavirin
Respiratory virusesReduce immunosuppressive drugs
Supportive care and, in some cases, the use of antivirals
Table 4 Prevention of viral infections kidney transplant recipients
CMVValganciclovir
Universal prophylaxis - Dose (mg) = (7 × BSA × eGFR) once a day
Preemptive therapy - Dose (mg) = ( 7 × BSA × eGFR) bd
EBVEBV viral load surveillance and preemptive therapy for EBV mismatched patients
BKPyVBK viral load monitoring and early identification of BK viremia
HSVAvoidance of visitors or health professionals who have HSV signs and symptoms
VZVAvoidance of visitors or health professionals who have VZV signs and symptoms. Vaccination including family members
Hepatitis B & CHepatitis B vaccination and immunity verified with Hepatitis B surface antibody screening following completion of the vaccination series
Respiratory virusesAvoidance of other individuals who have signs or symptoms of infection, hand hygiene, and use of droplet precautions for those suspected of having infection